Financials data is unavailable for this security.
View more
Year on year Intra-Cellular Therapies Inc grew revenues 85.51% from 250.31m to 464.37m while net income improved from a loss of 256.26m to a smaller loss of 139.67m.
Gross margin | 92.30% |
---|---|
Net profit margin | -14.07% |
Operating margin | -19.82% |
Return on assets | -8.46% |
---|---|
Return on equity | -9.90% |
Return on investment | -9.74% |
More ▼
Cash flow in USDView more
In 2023, Intra-Cellular Therapies Inc did not generate a significant amount of cash. However, Cash Flow from Investing totalled 105.54m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 124.20m for operations while cash generated from financing totalled 17.81m.
Cash flow per share | -0.8527 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 10.80 |
---|---|
Tangible book value per share | 10.80 |
More ▼
Balance sheet in USDView more
Current ratio | 7.66 |
---|---|
Quick ratio | 7.51 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼